Moderna(US:MRNA)2025-05-01 11:16Financial Performance - Moderna's total revenue for 1Q25 was $0.108 billion, a decrease of 35% compared to $0.167 billion in 1Q24[14] - Net product sales decreased by 49%, from $0.167 billion in 1Q24 to $0.086 billion in 1Q25[14] - The company reported a net loss of $0.971 billion in 1Q25, compared to a net loss of $1.175 billion in 1Q24, representing a 17% decrease in net loss[14] - Operating expenses were reduced by 19%, or $0.275 billion, from $1.433 billion in 1Q24 to $1.158 billion in 1Q25[8, 14] - Cash, cash equivalents, and investments decreased by 12%, from $9.5 billion at the end of 2024 to $8.4 billion as of March 31, 2025[16] Financial Outlook - The company anticipates total revenue for the full year 2025 to be between $1.5 billion and $2.5 billion[17] - Moderna expects to reduce costs by $1.4 billion to $1.7 billion by 2027[18] - The company is targeting cash breakeven in 2028[2] Pipeline and Product Development - Moderna has filed for approval of its next-generation COVID vaccine and RSV vaccine for older adults[23, 29] - The company's flu vaccine (mRNA-1010) exceeded case accruals required for Phase 3 interim efficacy analysis[12] - Moderna is expanding its oncology portfolio, including Checkpoint AIM-T (mRNA-4359)[12]